PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29911323-8 2018 CSE cotreatment with simvastatin and rosuvastatin significantly reduced p38MAPK activation, senescence (decrease in SA-beta-Gal) and SASP markers, GM-CSF, and TNF, but not IL-8, while increasing anti-inflammatory IL-10 in a dose-dependent manner. Rosuvastatin Calcium 37-49 tumor necrosis factor Homo sapiens 159-162 32955957-6 2021 After 12 months, rosuvastatin produced a significant decrease in mean serum levels of hsCRP (-0.28 mg/dL; p = .037), IL-6 (-2.1 pg/mL; p = .018) and TNF-alpha (-6.3 pg/mL; p = .004) in patients with MetS. Rosuvastatin Calcium 17-29 tumor necrosis factor Homo sapiens 149-158 32895874-8 2021 RESULTS: Rosuvastatin produced a significant decrease (p < 0.05) in lipids (total cholesterol, triglycerides, LDL-C); oxidative stress (oxLDL, oxHDL, MPO); inflammation (TNF-alpha); LCAT concentration; cIMT; significant increase in antiatherogenic HDL and cholesterol efflux (p < 0.05) and no change in apoA-I levels from baseline to 12 weeks of follow-up. Rosuvastatin Calcium 9-21 tumor necrosis factor Homo sapiens 170-179 25620256-0 2014 [MicroRNA-210 mediates the protective effect of rosuvastatin on human mesenchymal stem cells apoptosis induced by tumor necrosis factor-alpha]. Rosuvastatin Calcium 48-60 tumor necrosis factor Homo sapiens 114-141 29522792-6 2018 Of the statins investigated, only atorvastatin, pravastatin and rosuvastatin protected SH-SY5Y cells from LPS-induced decreases in cellular viability; this appeared mediated through reduced caspase 3/7 activation and was associated with decreased IL-1beta (atorvastatin, pravastatin) and/or TNF-alpha (atorvastatin, pravastatin, rosuvastatin). Rosuvastatin Calcium 64-76 tumor necrosis factor Homo sapiens 291-300 28417263-7 2017 Treatment with rosuvastatin decreased the production of nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha) and increased interleukin-10 (IL-10) in a dose-dependent manner. Rosuvastatin Calcium 15-27 tumor necrosis factor Homo sapiens 75-102 28417263-7 2017 Treatment with rosuvastatin decreased the production of nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha) and increased interleukin-10 (IL-10) in a dose-dependent manner. Rosuvastatin Calcium 15-27 tumor necrosis factor Homo sapiens 104-113 25771851-9 2015 Levels of inflammatory measures, TNF-alpha, IL-6 and ICAM-1 decreased significantly (p < 0.01) after treatment with rosuvastatin. Rosuvastatin Calcium 119-131 tumor necrosis factor Homo sapiens 33-42 25771851-14 2015 Rosuvastatin lowers the proinflammatory cytokines, especially IL-6 and TNF-alpha, which downregulates adhesion molecules and CRP production which in turns improves ED. Rosuvastatin Calcium 0-12 tumor necrosis factor Homo sapiens 71-80 25319951-6 2014 RESULTS: Compared with placebo, rosuvastatin treatment significantly reduced the incidence of periprocedural myocardial infarction (PMI) and levels of cardiac troponin I (cTnI) associated with decreased relative expression of serum miR-155, levels of inflammatory cytokines (INF-gamma, TNF-alpha, and IL-6), increased SHIP-1 expression and CD4(+)FoxP3(+)Treg percentage values (P < 0.05). Rosuvastatin Calcium 32-44 tumor necrosis factor Homo sapiens 286-295 25620256-1 2014 OBJECTIVE: To explore the effect and mechanism of rosuvastatin on tumor necrosis factor-alpha induced human mesenchymal stem cells (MSCs) apoptosis. Rosuvastatin Calcium 50-62 tumor necrosis factor Homo sapiens 66-93 25620256-5 2014 RESULT: TNF-alpha significantly induced human MSCs apoptosis in a concentration-dependent manner, and pretreatment with rosuvastatin significantly reduced MSCs apoptosis (caspase-3 assay: TNF-alpha+Statin group vs. TNF-alpha group: (1.63 +- 0.25) vs. (2.05 +- 0.36), P < 0.05). Rosuvastatin Calcium 120-132 tumor necrosis factor Homo sapiens 188-197 25620256-5 2014 RESULT: TNF-alpha significantly induced human MSCs apoptosis in a concentration-dependent manner, and pretreatment with rosuvastatin significantly reduced MSCs apoptosis (caspase-3 assay: TNF-alpha+Statin group vs. TNF-alpha group: (1.63 +- 0.25) vs. (2.05 +- 0.36), P < 0.05). Rosuvastatin Calcium 120-132 tumor necrosis factor Homo sapiens 188-197 25620256-7 2014 The protective effect of rosuvastatin on TNF-alpha induced MSCs apoptosis was largely abolished by co-treatment with 100 nmol/L antago-miRNA (TUNEL:TNF-alpha + Statin + antago-miR group vs. TNF-alpha + Statin group: (42.58 +- 6.71) % vs. (16.87 +- 9.27) %, P < 0.05). Rosuvastatin Calcium 25-37 tumor necrosis factor Homo sapiens 41-50 25620256-7 2014 The protective effect of rosuvastatin on TNF-alpha induced MSCs apoptosis was largely abolished by co-treatment with 100 nmol/L antago-miRNA (TUNEL:TNF-alpha + Statin + antago-miR group vs. TNF-alpha + Statin group: (42.58 +- 6.71) % vs. (16.87 +- 9.27) %, P < 0.05). Rosuvastatin Calcium 25-37 tumor necrosis factor Homo sapiens 148-157 25620256-7 2014 The protective effect of rosuvastatin on TNF-alpha induced MSCs apoptosis was largely abolished by co-treatment with 100 nmol/L antago-miRNA (TUNEL:TNF-alpha + Statin + antago-miR group vs. TNF-alpha + Statin group: (42.58 +- 6.71) % vs. (16.87 +- 9.27) %, P < 0.05). Rosuvastatin Calcium 25-37 tumor necrosis factor Homo sapiens 148-157 25620256-8 2014 CONCLUSION: Pretreatment with rosuvastatin can significantly improve the viability of human MSCs after TNF-alpha injury, the protective mechanism of rosuvastatin is partly mediated through miRNA-210 up-regulation. Rosuvastatin Calcium 30-42 tumor necrosis factor Homo sapiens 103-112 25620256-8 2014 CONCLUSION: Pretreatment with rosuvastatin can significantly improve the viability of human MSCs after TNF-alpha injury, the protective mechanism of rosuvastatin is partly mediated through miRNA-210 up-regulation. Rosuvastatin Calcium 149-161 tumor necrosis factor Homo sapiens 103-112 17577102-6 2007 RESULTS: Rosuvastatin decreased the extent of U937 adhesion to TNF-alpha-stimulated HUVEC. Rosuvastatin Calcium 9-21 tumor necrosis factor Homo sapiens 63-72 24467235-13 2014 SIGNIFICANCE: The decline in tlr-4 expression on blood monocytes and TNF-alpha plasma concentrations after 3 weeks of rosuvastatin treatment suggest a potential mechanism for the anti-inflammatory activity of rosuvastatin. Rosuvastatin Calcium 118-130 tumor necrosis factor Homo sapiens 69-78 24467235-13 2014 SIGNIFICANCE: The decline in tlr-4 expression on blood monocytes and TNF-alpha plasma concentrations after 3 weeks of rosuvastatin treatment suggest a potential mechanism for the anti-inflammatory activity of rosuvastatin. Rosuvastatin Calcium 209-221 tumor necrosis factor Homo sapiens 69-78 17928646-7 2007 Rosuvastatin and cerivastatin reverse the detrimental effects of TNF-alpha-induced down-regulation in eNOS protein expression and increase NO synthase activity by inhibiting HMG-CoA reductase and subsequent blocking of isoprenoid synthesis. Rosuvastatin Calcium 0-12 tumor necrosis factor Homo sapiens 65-74 24410968-6 2014 In the CRP-transgenic strain, we found that rosuvastatin treatment decreased circulating levels of inflammatory response markers IL6 and TNFalpha without decreasing circulating levels of human CRP. Rosuvastatin Calcium 44-56 tumor necrosis factor Homo sapiens 137-145 23289819-6 2013 The main goal was to determine the effect of rosuvastatin on plasma levels of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, and IL-10 after 72 hours of TBI. Rosuvastatin Calcium 45-57 tumor necrosis factor Homo sapiens 78-105 23289819-9 2013 The best-fit mixed model showed a significant effect of rosuvastatin on the reduction of tumor necrosis factor-alpha levels (p = 0.004). Rosuvastatin Calcium 56-68 tumor necrosis factor Homo sapiens 89-116 21222064-8 2011 Both ROS and PIT lowered plasma levels of high-sensitivity C-reactive protein (hsCRP), tumor necrosis factor (TNF)-alpha, and plasminogen activator inhibitor-1 (PAI-1). Rosuvastatin Calcium 5-8 tumor necrosis factor Homo sapiens 87-120 18082089-7 2007 Pharmacological treatment with either rosuvastatin or metformin lead to reductions in IL-6, TNFalpha, GSH and GPx levels and an increase in the SOD level, and there were significant interactions between the two treatment groups for these variables. Rosuvastatin Calcium 38-50 tumor necrosis factor Homo sapiens 92-100